# America Great Health

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/America Great Health).

## Overview

America Great Health is a U.S.-based pharmaceutical-preparations company that sells products through wholesale channels. Its disclosed operating model centers on product sales and bulk orders to U.S. wholesale accounts rather than subscription or service revenue.

## Products & services

• Pharmaceutical preparation products
• Bulk wholesale product orders
• U.S. product distribution
• Inventory-based sale of goods

- **Pharmaceutical preparations** (70%) — Product sales within the company’s pharmaceutical-preparations business.
- **Wholesale product orders** (20%) — Bulk orders placed by U.S. wholesale accounts and commercial buyers.
- **Other sale-of-goods activity** (10%) — Additional product transactions not separately identified in the disclosed reports.

- Pharmaceutical preparation products
- Bulk wholesale product orders
- U.S. product distribution
- Inventory-based sale of goods

## Customers

The company sells primarily to U.S. wholesale accounts, with bulk orders representing an important source of sales. Wholesale buyers purchase products for resale or downstream distribution, making account retention and order timing important to revenue. The reports do not identify specific retailers, distributors, healthcare systems, or consumer brands.

- **U.S. wholesale accounts** (primary) — Purchase pharmaceutical-preparation products in bulk for resale or distribution.
- **Commercial distributors** (secondary) — Source products for downstream supply to retailers and other commercial channels.
- **Retail and resale channels** (emerging) — Potential downstream outlets receiving products through wholesale relationships.

- U.S. wholesale accounts buying products in bulk
- Commercial distributors reselling pharmaceutical preparations
- Downstream retail channels supplied through wholesalers
- Buyers seeking packaged products for resale

## Geography

America Great Health’s disclosed operations and sales are concentrated in the United States. The March 2026 quarterly filing specifically attributes revenue changes to the temporary absence of major U.S. wholesale accounts, indicating that domestic customer concentration is important to operating performance.

- United States is the disclosed operating and sales market
- U.S. wholesale accounts drive bulk-order activity
- Domestic concentration links revenue to account retention
- No international revenue split is disclosed

## Strategy

The company’s stated priorities are to raise additional capital, fund working capital, and reach profitable operations. Short-term funding has included loans and advances from shareholders, while future execution depends on securing sufficient capital and rebuilding wholesale order volume.

- **Raise additional capital** (short-term) — The company requires external funding to maintain operations and support working capital.
- **Restore wholesale sales volume** (short-term) — Major wholesale accounts materially affect revenue because the business relies on bulk product orders.
- **Achieve profitable operations** (medium-term) — A sustainable profit base is needed to reduce dependence on external funding.

- Raise capital to support ongoing operations
- Secure working capital for inventory and obligations
- Rebuild volume from major wholesale accounts
- Pursue profitable operating performance
- Use shareholder funding to bridge liquidity needs

## Risks

America Great Health faces substantial going-concern and financing risk because it reports recurring losses, limited cash, negative working capital, and dependence on shareholder funding. Its wholesale-centered model also creates customer-concentration and order-timing risk, while pharmaceutical product sales remain exposed to inventory obsolescence, regulatory requirements, competition, and product-quality issues.

- **Going-concern uncertainty** [critical] — The filing cites recurring losses, cash used in operations, negative working capital, and substantial doubt about continuing operations.
- **External financing dependence** [high] — Working capital needs have been funded by short-term loans and advances from shareholders.
- **Wholesale customer concentration** [high] — The absence of major U.S. wholesale accounts caused a significant year-over-year sales contraction.
- **Inventory obsolescence** [medium] — Slow-moving or obsolete pharmaceutical inventory may require write-downs to net realizable value.
- **Regulatory and product-quality exposure** [high] — Pharmaceutical preparations require compliance with applicable manufacturing, labeling, safety, and distribution standards.

- Limited cash and negative working capital constrain operations
- Dependence on shareholder funding creates financing risk
- Loss of major wholesale accounts can sharply reduce sales
- Inventory may become obsolete or require valuation reserves
- Pharmaceutical products face regulatory and quality risks
- Competition may pressure pricing and wholesale demand

## Accounting

Revenue is recognized under Topic 606 after identifying enforceable contracts, performance obligations, transaction prices, and satisfaction of those obligations, so shipment and fulfillment timing can affect reported sales. Inventory is measured at the lower of FIFO cost or net realizable value, while management estimates affect obsolete-inventory reserves, share-based service valuations, deferred tax assets, and debt-extinguishment gains.

- **Revenue recognition under Topic 606** — Timing of wholesale delivery and fulfillment affects reported revenue and quarterly comparability.
- **Inventory valuation** — Write-downs reduce inventory and gross profit; the company recorded a $9,000 provision.
- **Management estimates** — Changes in valuation assumptions can affect expenses, equity, and reported losses.
- **Deferred tax asset valuation allowance** — A valuation allowance of $7,784,371 at March 31, 2026 limits recognized tax benefits.
- **Debt extinguishment gains** — The reported nine-month 2026 net income included a $1,395,000 debt-extinguishment gain.
- **Fair value measurements** — Changes in valuation inputs could affect reported assets, liabilities, or gains and losses.

- Topic 606 links revenue to contract fulfillment
- Wholesale shipment timing can affect quarterly sales
- FIFO inventory is tested against net realizable value
- Obsolescence reserves affect inventory and gross profit
- Deferred tax assets carry a substantial valuation allowance
- Debt extinguishment gains can distort reported earnings

---

*Last updated: 2026-09-08T05:12:07.017652+00:00*